Alisa Bank’s H2 results were quite in line with our estimates.
Aspo’s Q4 figures came in soft relative to estimates as all three segments missed profitability esti...
H2 2023 net sales and EBIT missed our estimates, yet profitability was better than expected excl.
Marimekko’s Q4 figures missed our estimates for net sales and adj.
Starbreeze's year-end report for 2023 caused a stock drop of about 15%.
Redeye leaves an initial comment following the Q4 report published by Magle this morning.
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently an...
Redeye believes 2024 could better demonstrate Sedana Medical’s European expansion and increase the c...
Minor '24e-'25e EBITDA estimate changes We deem positive EBIT in '24 to be a credible target EV/ARR ...
Redeye updates its estimates following Sozap’s Q4 report.
Redeye reduces its sales and profitability forecast following softer Q4-figures.
Paper EBITDA PLN 120m vs. ABGSCe PLN 108m Weak performance from Rottneros drags group results down P...
Redeye states that the report aligned with preliminary figures and showed net sales in line with est...
Redeye retains its positive view of Formpipe following a Q4 matching our forecasts.
Redeye återkommer med en update efter BioArctics Q4-rapport som kom in lägre vår förväntan, vilket d...
Redeye regard Stille's Q4 report as strong as it came in slightly above our estimates in terms of bo...
Årsbokslutet för 2023 från Starbreeze skapade ett kursras på omkring 15% i aktien.
Sales growth +22%, ARR +14% y-o-y in Q4 We raise estimates on the new defence order Good outlook for...
We lower '24e and '25e adj. EBITA by 3% and 6% 5% EBITA growth in '24e driven by HQ cost cuts '24e E...
